¹û¶³Ó°Ôº

Links

ucl.ac.uk/medicine/amyloidosis">¹û¶³Ó°Ôº Centre for Amyloidosis and Acute Phase Proteins

As reported in the Financial Times today, GlaxoSmithKline (GSK) has announced it aims to sign up 10 academic 'superstars' for long term partnerships to develop medicines more cost effectively.

¹û¶³Ó°Ôº Business is delighted to announce that the first academic 'superstar' to be chosen is Professor Mark Pepys (¹û¶³Ó°Ôº Division of Medicine).

Professor Pepys started up the ¹û¶³Ó°Ôº-spin out Pentraxin Therapeutics, which is developing a treatment for a rare form of amyloidosis.Ìý

Professor Pepys said:Ìý"It's a wonderful idea and we are delighted to be working with GSK to develop new medicines for patients."

GSK aims to work closely with leading external medical researchers until the launch of a new drug. This will allow GSK to tap their expertise while providing them with facilities, funding and incentives to be paid if a treatment proves successful.

---

Related News

About Pentraxin Therapeutics Ltd

Pentraxin Therapeutics Ltd is a company spun out of ¹û¶³Ó°Ôº by ¹û¶³Ó°Ôº Business (¹û¶³Ó°ÔºB). Formed in 2001, it holds all the intellectual property and proprietary knowledge emanating from the research of Professor Mark Pepys at ¹û¶³Ó°Ôº. ÌýMajor IP within Pentraxin covers treatments for amyloidosis and amyloid-related diseases such as Alzheimer's disease and type II diabetes, as well as targeting the pathogenic effects of C‑reactive protein in cardiovascular disease and inflammatory diseases.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at

About ¹û¶³Ó°ÔºB

¹û¶³Ó°Ôº Business plc is responsible for commercialising innovations arising from the research base at ¹û¶³Ó°Ôº, one of the UK's leading research-led universities. ¹û¶³Ó°Ôº Business undertakes a broad range of knowledge transfer activities, covering the facilitation of consultancy and collaborative research engagements through to technology transfer, company incubation and investment. More information on ¹û¶³Ó°Ôº Business can be found at